Clinical Trial Update: Innovative Biomarkers of Cardiovascular Complications Associated With Second-generation Bruton Tyrosine Kinase Inhibitor Treatments: a Single-center Cohort Study

View source ↗

Summary

A single-center cohort study is assessing biomarkers of cardiovascular complications in patients treated with second-generation BTK inhibitors acalabrutinib or …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Mantle Cell Lymphoma
• Small Lymphocytic Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• Acalabrutinib (acalabrutinib)
• Zanubrutinib (zanubrutinib)

Snippet

Sponsor: Centre Hospitalier Universitaire Dijon | Conditions: Treatment With Second-generation Bruton's Tyrosine Kinase Inhibitors (Acalabrutinib, Zanubrutinib) | Status: RECRUITING